Date

Speaker

Institute

Title

Sep 16

Xue-Qiao Zhao, MD
Research Associate Professor, Division of Cardiology

University of Washington

Vascular Protective Effects of Lowering LDL Plus Increasing HDL

  Lecture Objectives:

· Identify some of the imaging tools (QCA, carotid MRI, carotid ultrasound and IVUS) to study atherosclerosis characteristics

· Understand the vascular protective effects of lowering LDL plus increasing HDL

· Discuss the clinical implications of the vascular protective effects derived from lowering LDL, plus increasing HDL

Oct 21

Richard L. Page, MD
Professor of Medicine, Robert A. Bruce Endowed Chair in Cardiovascular Research, Head, Division of Cardiology

University of Washington

Atrial Fibrillation – Where Do We Go From Here?

  Lecture Objectives:

· Understand pathophysiology of atrial fibrillation

· Be able to choose therapy for atrial fibrillation based on patient characteristics

· Understand newer invasive and pharmacologic option s for atrial fibrillation

Nov 18

Frank W. Smart, MD
Director, Advanced Heart Failure/Cardiac Transplantation, Texas Heart Institute
Associate Professor of Medicine, Baylor Medical School, Houston, Texas

Texas Heart Institute, Baylor School of Medicine

Left Ventricular Assist Device Therapy End-Stage CHF

  Lecture Objectives:

· Discuss the use of left ventricular assist device therapy for patients with end-stage cardiomyopathy

· Understand patient selection for left ventricular device therapy

· Discuss the left ventricular assist device therapy risk factors for transplant and coronary artery disease

Dec 16

Bryan Kestenbaum, MD
Assistant Professor
Division of Nephrology, Department of Medicine

University of Washington

Cardiovascular Disease in the Setting of Chronic Renal Failure

  Lecture Objectives:

· Scope of cardiovascular disease among the chronic renal disease population

· Traditional risk factors for cardiovascular disease among patients with renal disease

· Non-traditional risk factors for cardiovascular disease among patients with renal disease

Jan 20

James H. O’Keefe, MD
Director, Preventive Cardiology Program

Mid America Heart Institute, Kansas City, Missouri

Improving Prognosis of Heart Disease and Diabetes

  Lecture Objectives:
· Understand the importance of insulin resistance

· Know the ideal diet for improving health and CV risks

· Understand how to correct the increased risk of sudden cardiac death in diabetes

Feb 17

John Gorcsan III, MD
Professor of Medicine,
Division of Cardiology,
Director of Echocardiography

University of Pittsburgh, Pittsburgh, Pennsylvania

Dyssynchrony and Predictors of Response to Pacing Therapy:  Mechanisms and Mechanics

Lecture Objectives:
· Identify the predictors of response to pacing therapy

· Understand the mechanisms and mechanics of dyssynchrony
· Enhance understanding of the role of pacing therapy in clinical practice

Mar 17

Gust H. Bardy, MD
Clinical Professor of Medicine, Cardiology

University of Washington and President, Seattle Institute for Cardiac Research

A Cynic’s View of Device Trials in Heart Failure or Why the Aliens Won’t Land

Lecture Objectives:
· How to constrain variables in Clinical Trials
· Meaningful endpoints in Clinical Trials of Heart Failure
· How to detect Bias in trial design (It’s in the methods, not the results.)

April 21

John C. Rutledge, MD, Professor and Chief, Division of Endocrinology, Clinical Nutrition and Vascular Medicine

University of California – Davis, Sacramento, California

The Postprandial State:  Foods for Health and Disease

Lecture Objectives:
· Review the vascular physiology and pathophysiology associated with the postprandial state.
· Discuss how triglyceride-rich lipoproteins could induce vascular disease
· Review how treatment guidelines relate to the postprandial state.

*May 12, 2^nd Friday

Jeffrey L. Probstfield, MD, Professor of Medicine, Division of Cardiology, Associate Director for Education, General Clinical Research Center, University of Washington; Affiliate Member, Fred Hutchinson Cancer Research Center

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington

Homocysteine, a risk factor for CVD!?  HOPE 2, NORVIT and VISP sound sour notes for vitamin therapy – clear outcomes, but complex reasons”

Lecture Objectives:

· Discuss:  Homocysteine is Thought to be a Risk Factor for CVD.
· Understand that Vitamin B Therapy Reduces levels of Homocysteine.

· Understand that Vitamin B Therapy Does Not Reduce Levels of CVD Events

Jun 16

Terry B. Gernsheimer, MD, Associate Professor of Medicine, and PSBC Director of Medical Transfusion Services, UW Medical Center Puget Sound Blood Center

University of Washington and Puget Sound Blood Center

Heparin Induced Thrombocytopenia:  Pathophysiology, Diagnosis and Therapy

Lecture Objectives:
· Understand the pathophysiologic mechanisms at work in Heparin Induced Thrombocytopenia, HIT (T)
· Uses of diagnostic testing in HIT
· Understand appropriate use of available anticoagulants for HIT